Surajeet Das Gupta, Sushmi Dey

Stories by Surajeet Das Gupta, Sushmi Dey

RCom to raise Rs 5,000 cr by selling real estate

RCom to raise Rs 5,000 cr by selling real estate

Rediff.com   3 Jul 2014

The company will use the proceeds to part-repay its debt, which stands at Rs 34,000 crore (Rs 340 billion) even after the recent qualified institutional placement of its shares. An RCom board committee recently approved the sale of these assets.

Airtel braces up for Reliance challenge

Airtel braces up for Reliance challenge

Rediff.com   11 Jun 2014

Unlike Reliance Jio's focus on 4G, it plans to segment the data market based on device prices and spectrum.

Drug makers seek out-of-court settlement in clinical trial cases

Drug makers seek out-of-court settlement in clinical trial cases

Rediff.com   10 Jun 2014

In a letter to health minister Harsh Vardhan, the Indian Pharmaceutical Alliance, an industry body representing leading pharma companies, including Sun Pharma, Lupin, Dr Reddy's Labs, Cadila Health and Glenmark, stressed the need for an out-of-court settlement with health activists fighting for the rights of clinical trial participants.

Drug makers told to give pricing details in 10 days

Drug makers told to give pricing details in 10 days

Rediff.com   6 Jun 2014

The Drug (Prices Control) Order implemented in May last year brought into its purview 652 packs of 348 formulations.

Now, buy medicines and stents on EMI

Now, buy medicines and stents on EMI

Rediff.com   5 Jun 2014

The company did not respond to specific queries on the project's expansion.

FDI in defence: Investment of up to 49% may be allowed without tech transfer

FDI in defence: Investment of up to 49% may be allowed without tech transfer

Rediff.com   4 Jun 2014

FDI in the defence sector during 2000-2014 has been a meagre $4.94 billion, despite the total FDI flow into the country across sectors standing at $321.81 billion.

Telcos may hike data tariff

Telcos may hike data tariff

Rediff.com   28 May 2014

The market could see a fresh round of tariff war, similar to what happened in the voice market a few years ago.

The puzzle of India's lack of manufacturing job growth

The puzzle of India's lack of manufacturing job growth

Rediff.com   21 May 2014

Top companies added employees at 3% CAGR from 2003-04 to 2013-14, while revenues grew at 18%.

Indian drug cos to benefit as US expedites generic clearances

Indian drug cos to benefit as US expedites generic clearances

Rediff.com   12 May 2014

Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.

Indian handset companies import most of their devices

Indian handset companies import most of their devices

Rediff.com   28 Apr 2014

Components manufactured in India are low-value products like casing and box packaging that constitute 5% of the bill for materials required in phone manufacturing.

Novartis-Glaxo deal signals pharma firms don't have it easy

Novartis-Glaxo deal signals pharma firms don't have it easy

Rediff.com   24 Apr 2014

Experts say despite it being a global deal, the transaction will have to undergo CCI scrutiny because of the scale of operations.

Novartis-GSK-Eli Lilly deal may affect Indian market

Novartis-GSK-Eli Lilly deal may affect Indian market

Rediff.com   23 Apr 2014

On Tuesday, Novartis agreed to buy GSK's oncology products business for $14.5 billion, while selling its vaccines business, excluding flu, to GSK for $7.1 billion.

ICAI to ban three auditors in Satyam case

ICAI to ban three auditors in Satyam case

Rediff.com   23 Apr 2014

ICAI has also imposed a fine of Rs 5 lakh on each of the three accused in Satyam case.

Suzuki has to double equity in Gujarat arm

Suzuki has to double equity in Gujarat arm

Rediff.com   23 Apr 2014

Removal of mark-ups to be paid by Maruti, other changes could raise funding need to Rs 6,000 crore.

Ranbaxy buy in line with Sun's strategy

Ranbaxy buy in line with Sun's strategy

Rediff.com   17 Apr 2014

The company buys distressed assets across the globe and turns them around to not only add to its books but also its product pipeline and regions.

Regulatory pain for GSK's Crocin Advance

Regulatory pain for GSK's Crocin Advance

Rediff.com   28 Mar 2014

The NPPA letter was issued to GSK on Wednesday.

Consumers may have to pay more for insulin

Consumers may have to pay more for insulin

Rediff.com   21 Mar 2014

Apart from Wockhardt, only Biocon manufactures insulin analog indigenously.

24 private hospitals get showcause notices

24 private hospitals get showcause notices

Rediff.com   20 Mar 2014

What started as a mere payment delay seems to have grown into a tussle between the government and leading private hospitals, empanelled under the Central Government Health Scheme.

Why is Novartis likely to lose Tiamulin drug licence?

Why is Novartis likely to lose Tiamulin drug licence?

Rediff.com   19 Mar 2014

Legal experts and official sources said the alleged submission of fake documents can also lead to criminal charges against Novartis.

Maruti's Gujarat plan: Mutual Fund cos head to Sebi, LIC

Maruti's Gujarat plan: Mutual Fund cos head to Sebi, LIC

Rediff.com   7 Mar 2014

LIC is one of the largest Indian shareholders in the country's largest car maker, with a 6.93% stake.